Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00861146
Other study ID # 0804003723
Secondary ID R01AA011197
Status Completed
Phase Phase 2
First received
Last updated
Start date April 2009
Est. completion date March 2013

Study information

Verified date April 2020
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The majority of individuals with alcohol problems remain current smokers, and the negative health consequences of smoking among these individuals are substantial. This study will investigate the impact of smoking cessation interventions initiated during intensive alcohol treatment on processes reflecting risk of alcohol relapse.


Description:

Objectives:

Most alcohol and drug treatment programs do not systematically address cigarette smoking during treatment. One obstacle is a concern that smoking cessation early in recovery might increase risk of alcohol relapse. This study followed patients enrolled in intensive outpatient alcohol treatment to compare the effects of a Concurrent Smoking Cessation (CSC) intervention to a Deferred Smoking Cessation (DSC) control group on process measures reflecting risk of alcohol relapse.

Research Design:

Participants were enrolled in intensive outpatient alcohol treatment and then randomized to CSC or DSC groups in a 2:1 ratio. The CSC group received smoking treatment concurrent with intensive alcohol treatment and the DSC group received smoking treatment three months after alcohol treatment. The smoking treatment protocol included behavioral counseling, contingency management with voucher rewards for verified smoking abstinence, and prescribed nicotine patch and gum. During a three-month period after the CSC target smoking quit date, both groups of subjects were asked to participate in a prospective daily monitoring procedure, calling into an Interactive Voice Response system once a day to complete self-report assessments of relapse risk factors. By comparing participants in the CSC group composed of many participants who have stopped smoking with the DSC group who are expected to continue smoking during this daily monitoring period, we will determine the impact of smoking cessation on alcohol relapse risk factors.

Methodology:

This study was conducted in the substance abuse day treatment programs located at Newington and West Haven campuses of VA Connecticut Healthcare System. These are three-week treatment programs meeting Monday-Friday for 4-5 hrs/day. Participants were recruited either before or soon after day program admission. Participants 151 individuals that are 18 years of age or older, meet Diagnostic and Statistical Manual-IV (DSM-IV) criteria for current alcohol abuse or dependence, report currently smoking 1 or more cigarettes per day, and are screened for medical contraindications for nicotine patch and gum use. Dependent variables are process assessments reflecting alcohol relapse risk obtained using daily Interactive Voice Response (IVR) technology. These relapse risk processes include alcohol craving, negative affect, alcohol abstinence self efficacy, alcohol outcome expectancies, motivation for alcohol abstinence, and self-control demands. Given the mixed results from previous clinical trials, we conducted bidirectional tests of the hypothesis that smoking cessation has an impact on alcohol relapse risk factors, examining whether smoking cessation leads to increased or decreased alcohol relapse risk.


Recruitment information / eligibility

Status Completed
Enrollment 151
Est. completion date March 2013
Est. primary completion date March 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- DSM-IV criteria for alcohol abuse or dependence

- Age 18 or older

- English speaking

- Smoking 1 or more cigarettes/day

- Male or female veterans eligible for VA healthcare

- Female nonveterans also eligible

Exclusion Criteria:

- Allergy or hypersensitivity to nicotine or adhesives used in nicotine patch

- Weigh less than 100 lbs

- Lack of interest in stopping smoking

- Pregnant or lactating females or females not practicing acceptable form of contraception

Study Design


Intervention

Behavioral:
behavioral counseling plus contingency management
Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum

Locations

Country Name City State
United States VA Connecticut Healthcare System Newington Connecticut
United States VA Connecticut Healthcare System West Haven Connecticut

Sponsors (2)

Lead Sponsor Collaborator
Yale University National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Smoking Abstinence 7-day point prevalence smoking abstinence verified by breath carbon monoxide missing coded as smoking 12 weeks
Primary Smoking Abstinence 7-day point prevalence smoking abstinence verified by breath carbon monoxide missing coded as smoking 2 weeks
Secondary Proportion of Days Heavy Drinking Heavy drinking days were defined as days with > 6 standard drinks per day for men and > 4 standard drinks per day for women. This measure examined the proportion of days heavy drinking across 28 days in follow-up weeks 9-12. follow-up weeks 9-12
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06021652 - Feasibility, Adoption and Efficacy of A Virtual Reality Smoking Cessation Program for Patients Undergoing Lung Cancer Screening N/A
Completed NCT02735382 - EHR-Based and Fax-Based Referral to a Tobacco Quitline: A Comparative Study N/A
Completed NCT02557919 - Families Reduce Exposure to Smoke at Home N/A
Completed NCT01570595 - Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV Phase 1/Phase 2
Completed NCT00786149 - Improving Varenicline Adherence and Outcomes in Homeless Smokers Phase 3
Completed NCT00387946 - Efficacy and Safety of Dianicline Treatment as an Aid to Smoking Cessation in Cigarette Smokers (AMERIDIAN) Phase 3
Completed NCT00218452 - Smoking Cessation for Young Adults Who Binge Drink - 1 Phase 0
Completed NCT00124683 - Treating Nicotine Dependence in Schizophrenic Individuals: Effectiveness of Bupropion - 1 Phase 2
Recruiting NCT04610931 - Study of the Effectiveness of a Virtual Reality Treatment in the Management of Smoking Cessation N/A
Enrolling by invitation NCT06042361 - Enhancing Equity in Smoke-free Housing N/A
Recruiting NCT04827420 - Mi QUIT CARE (Mile Square QUIT Community-Access-Referral-Expansion) N/A
Recruiting NCT04994444 - Preloading With Nicotine Replacement Therapy in HIV-positive Smokers to Improve Self-Efficacy and Quit Attempts Phase 2/Phase 3
Completed NCT05560243 - Tobacco Cessation Tailored to Patients Living With HIV (PLWH) in Brazil N/A
Completed NCT02721082 - Changing the Default for Tobacco Treatment Phase 4
Completed NCT01885221 - A Multi-Media Approach to Partner Support in Smokeless Tobacco Cessation (UCare-ChewFree) N/A
Completed NCT03445507 - Effectiveness of a Chat Bot for Smoking Cessation: a Pragmatic Trial in Primary Care. N/A
Completed NCT04540081 - Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer N/A
Completed NCT03714191 - Optimizing the Tobacco Cessation Clinical Decision Support Tool.
Completed NCT03553992 - An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers N/A
Completed NCT01699828 - Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET Phase 1/Phase 2